Part D Coverage for Cholesterol Drugs: Statins & PCSK9s

If you take a cholesterol medication — or your doctor wants you to start one — the first question is usually simple: what will it cost under my Part D plan? The answer depends heavily on which drug class you're in. Plain statins are among the cheapest drugs in Medicare, while newer PCSK9 inhibitors can be among the most expensive. Here's how Part D treats each one in 2026.

Statins: The Low-Cost Workhorses

Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin) are long past their patents, and Medicare Part D reflects that. Generics typically sit on Tier 1 or Tier 2, which means copays of a few dollars for a 30-day supply — and some plans charge $0, especially for preferred generics or 90-day mail-order fills.

Because the drug cost is so low, the deductible barely matters for statins: even plans with the maximum $615 deductible usually let you pay the small copay from day one.

• 90-day supplies often save more. A 90-day fill at a preferred pharmacy frequently costs less than three 30-day fills.
• Brands cost more when they exist. Brand-name versions like Lipitor or Crestor sit on higher tiers when generics are available — ask your doctor about switching to the generic if cost is an issue.

Ezetimibe and Bempedoic Acid: The Middle Tier

If statins alone don't get LDL where it needs to be, doctors often add ezetimibe (Zetia) — generic, inexpensive, and usually Tier 2. Bempedoic acid (Nexletol), a newer add-on for statin-intolerant patients, generally lands on Tier 3 or 4 with prior authorization on many plans. Check your plan's formulary before you switch, because tier placement varies by plan.

PCSK9 Inhibitors: Specialty Tier, Prior Authorization Required

PCSK9 inhibitors — evolocumab (Repatha) and alirocumab (Praluent), both self-injectable antibodies — are among the most effective LDL-lowering drugs available, cutting LDL roughly in half on top of statins. They also carry a list price of roughly $5,850 to $6,300 a year.

On Part D plans, they typically land on the specialty tier, which means:

1. You pay a percentage, not a flat copay. Specialty-tier cost sharing is usually a coinsurance percentage of the drug's cost.
2. Prior authorization is required. Nearly every plan asks for proof of a qualifying diagnosis (such as familial hypercholesterolemia or established cardiovascular disease), documentation of trials on statins (often two statins at the highest tolerated dose), and evidence that LDL remains above the plan's threshold after cheaper options.
3. Quantity limits apply. Plans typically limit fills to the labeled monthly dose.

The good news: coverage criteria have been loosening in 2026, with some major insurers dropping requirements such as a mandatory ezetimibe trial before approving a PCSK9 inhibitor. And if your doctor documents statin intolerance or failure properly, many initial denials are overturned on appeal.

The $2,100 Cap Changes the Math for Expensive Drugs

Before 2025, a specialty-tier drug like Repatha could mean hundreds of dollars a month with no ceiling. That changed: in 2026, your total out-of-pocket spending across all Part D drugs is capped at $2,100. Once you hit that cap, you pay $0 for covered drugs for the rest of the year.

That means the practical worst case for a PCSK9 inhibitor in 2026 is $2,100 for the year — and that cap is shared across all your Part D medications, so a patient already taking other expensive drugs may pay little extra for the PCSK9 inhibitor. You can also spread that $2,100 across the year in level monthly payments through the Medicare Prescription Payment Plan.

One caveat: manufacturer copay cards (which advertise as little as $5 a month for commercially insured patients) cannot be used with Medicare. Don't count on them.

What About Injectable Cholesterol Drugs Given at the Doctor's Office?

Not every cholesterol drug is a Part D drug. Inclisiran (Leqvio), a twice-yearly injection given in a clinic, is typically covered under Medicare Part B (the medical benefit) rather than Part D when administered in a doctor's office — which means the 20% Part B coinsurance rules apply instead of the Part D specialty tier. Which part covers it depends on how and where the drug is administered, so confirm with both your plan and your doctor's office.

What To Do Before You Switch or Start

• Check the formulary first. Tier placement and prior authorization rules differ from plan to plan — even between plans from the same insurer.
• Document statin trials. If you're headed toward a PCSK9 inhibitor, make sure your records show which statins you tried, the doses, and why they stopped working. This paperwork is what wins prior authorizations.
• Ask about step therapy. Some plans require trying ezetimibe before a PCSK9 inhibitor; know your plan's sequence before your appointment.
• Use the $2,100 cap in your planning. If you're considering a plan change during AEP (October 15 – December 7), remember that an expensive drug's annual cost is bounded by the cap regardless of tier.

Bottom line: In 2026, generic statins are cheap on Part D and PCSK9 inhibitors are expensive-but-capped — the $2,100 annual out-of-pocket maximum limits what any covered cholesterol drug can cost you, even a ~$6,000-a-year injectable.